Mar 1, 2018 |
BOSTON, March 01, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP), a biotechnology company focused on development of next generation ...
|
|
Feb 13, 2018 |
BOSTON, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP), today announced that management will host a conference call and webcast slide presentation on Thursday, March 1, at 4:30 p.m. ET to provide a corporate update and discuss financial results for the fourth quarter and year ended Dec. 31, 2017. ...
|
|
Feb 12, 2018 |
BOSTON, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP), a biotechnology company focused on development of...
|
|
Feb 6, 2018 |
BOSTON, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today responded to unfounded rumors regarding possible financing plans of the Company. Management states that it knows of no developments at the Company that would be the cause of the recent volatility and decline in the stock price. ...
|
|
Jan 9, 2018 |
- Controlled IL-12 advancing as drug platform as monotherapy and in combination with OPDIVO® (nivolumab) -- Non-viral T-cell platform shows potential for efficacy, scalability and cost reduction for multiple oncology targets - BOSTON, Jan. 09, 2018 (GLOBE NEWSWIRE...
|
|
Dec 21, 2017 |
BOSTON, Dec. 21, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 11, 2018 at 10 a.m. PST. The presentation will include...
|
|
Dec 10, 2017 |
— Clinical data show continued survival benefit, tumor response, and multi-year persistence of Sleeping Beauty-modified CD19-specific CAR+ T cells —— Point-of-care CD19-specific CAR+ T cells co-expressing mbIL15 with control switch show ...
|
|
Nov 20, 2017 |
— Controlled IL-12 gene therapy turns cold tumors hot —— MRI indicates decreasing size of brain tumor lesions in several patients —— Median overall survival for patients with recurrent glioblastoma (rGBM) maintained at 12.5 months in 20mg cohort with longer...
|
|
Nov 17, 2017 |
BOSTON, Nov. 17, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company developing new gene and cell-based immunotherapies for cancer, today announced that it will host a conference call and webcast slide presentation on Monday, November 20, 2017 at 10:15 a.m. ET to discuss updated clinica...
|
|
Nov 10, 2017 |
BOSTON, Nov. 10, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that David Mauney, M.D., CBO and interim COO, will present at the Stifel 2017 Healthcare Conference in New York on Tuesday, November 14, 2017 at 11:00 a.m. ET. To access a live audio webcast of the pre...
|
|